PEPGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PEPGEN INC. (PEPG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.68 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 271.27K shares, a 53.03% decline year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.41M shares, a 104.66% increase year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 167.72K shares, a 16.41% decline year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.92M shares, a 11.70% decline from fiscal 2024.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.18M shares, a 52.97% increase from fiscal 2023.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.42M shares, a 7.92% decline from fiscal 2022.
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.54M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 271.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.68M shares 10-Q · filed 2026-08-06 | 2.84M shares derived: sum of 3 quarters · filed 2026-08-06 | 2.84M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 2.41M shares 10-Q · filed 2026-05-12 | 2.57M shares derived: sum of 2 quarters · filed 2026-05-12 | 2.57M shares derived: sum of 3 quarters · filed 2026-05-12 | 3.15M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 167.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | 167.72K shares derived: sum of 2 quarters · filed 2026-03-04 | 745.23K shares derived: sum of 3 quarters · filed 2026-03-04 | 1.92M shares 10-K · filed 2026-03-04 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 577.50K shares derived: sum of 2 quarters · filed 2025-11-12 | 1.75M shares 10-Q · filed 2025-11-12 | 1.95M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 577.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.75M shares 10-Q · filed 2025-08-07 | 1.95M shares derived: sum of 3 quarters · filed 2025-08-07 | 2.45M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.18M shares 10-Q · filed 2025-05-08 | 1.38M shares derived: sum of 2 quarters · filed 2025-05-08 | 1.88M shares derived: sum of 3 quarters · filed 2025-05-08 | 2.03M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 200.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | 700.72K shares derived: sum of 2 quarters · filed 2025-02-24 | 858.73K shares derived: sum of 3 quarters · filed 2025-02-24 | 2.18M shares 10-K · filed 2025-02-24 |
| 2024-09-30 | 500.07K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 658.08K shares derived: sum of 2 quarters · filed 2024-11-07 | 1.97M shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 158.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.47M shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 1.32M shares 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | 1.42M shares 10-K/A · filed 2024-03-29 | |||
| 2022-12-31 | 1.54M shares 10-K · filed 2023-03-23 | |||
| 2022-03-31 | 176.96K shares 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |